Abstract
Screening of the liver for hepatic lesion detection and characterization is usually performed with either ultrasound or CT. However, both techniques are suboptimal for liver lesion characterization and magnetic resonance (MR) imaging has emerged as the preferred radiological investigation. In addition to unenhanced MR imaging techniques, contrast-enhanced MR imaging can demonstrate tissue-specific physiological information, thereby facilitating liver lesion characterization. Currently, the classes of contrast agents available for MR imaging of the liver include non-tissue-specific extracellular gadolinium chelates and tissue-specific hepatobiliary or reticuloendothelial agents. In this review, we describe the MR features of the more common focal hepatic lesions, as well as appropriate imaging protocols. A special emphasis is placed on the clinical use of non-specific and liver-specific contrast agents for differentiation of focal liver lesions. This may aid in the accurate diagnostic workup of patients in order to avoid invasive procedures, such as biopsy, for lesion characterization. A diagnostic strategy that considers the clinical situation is also presented.
Similar content being viewed by others
References
Perilongo G, Shafford EA (1999) Liver tumours. Eur J Cancer 35(6):953–958 discussion 958–959
Jones EC, Chezmar JL, Nelson RC, Bernardino ME (1992) The frequency and significance of small (less than or equal to 15 mm) hepatic lesions detected by CT. AJR Am J Roentgenol 158(3):535–539
Ba-Ssalamah A, Fakhrai N, Matzek WK, Herneth AM, Stadler A, Bastati N, Herold CJ, Schima W (2007) Magnetic resonance imaging of liver malignancies. Top Magn Reson Imaging 18(6):445–455
Morana G, Salviato E, Guarise A (2007) Contrast agents for hepatic MRI. Cancer Imaging 7(Spec No A):S24–S27
Ersoy H, Rybicki FJ (2007) Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 26(5):1190–1197
Niendorf HP, Alhassan A, Geens VR, Clauss W (1994) Safety review of gadopentetate dimeglumine. Extended clinical experience after more than five million applications. Invest Radiol 29(Suppl 2):S179–S182
Semelka RC, Helmberger TK (2001) Contrast agents for MR imaging of the liver. Radiology 218(1):27–38
Reimer P, Schneider G, Schima W (2004) Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 14(4):559–578
Hammerstingl R, Zangos S, Schwarz W, Rosen T, Bechstein WO, Balzer T, Vogl TJ (2002) Contrast-enhanced MRI of focal liver tumors using a hepatobiliary MR contrast agent: detection and differential diagnosis using Gd-EOB-DTPA-enhanced versus Gd-DTPA-enhanced MRI in the same patient. Acad Radiol 9(Suppl 1):S119–S120
Schima W, Saini S, Petersein J, Weissleder R, Harisinghani M, Mayo-Smith W, Hahn PF (1999) MR imaging of the liver with Gd-BOPTA: quantitative analysis of T1-weighted images at two different doses. J Magn Reson Imaging 10(1):80–83
Zech CJ, Herrmann KA, Reiser MF, Schoenberg SO (2007) MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci 6(1):43–52
Halavaara J, Breuer J, Ayuso C, Balzer T, Bellin MF, Blomqvist L, Carter R, Grazioli L, Hammerstingl R, Huppertz A, Jung G, Krause D, Laghi A, Leen E, Lupatelli L, Marsili L, Martin J, Pretorius ES, Reinhold C, Stiskal M, Stolpen AH (2006) Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT-a multicenter trial. J Comput Assist Tomogr 30(3):345–354
Stroszczynski C, Gaffke G, Gnauck M, Streitparth F, Wieners G, Lopez-Haninnen E (2004) Current status of MRI diagnostics with liver-specific contrast agents. Gd-EOB-DTPA and Gd-BOPTA. Radiologe 44(12):1185–1191
Huppertz A, Haraida S, Kraus A, Zech CJ, Scheidler J, Breuer J, Helmberger TK, Reiser MF (2005) Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 234(2):468–478
Morana GGL, Schneider G et al (2002) Hypervascular hepatic lesions: dynamic late enhancement pattern with Gd-BOPTA. Acad Radiol 9(Suppl 2):S476–S479
Oudkerk M, Torres CG, Song B, Konig M, Grimm J, Fernandez-Cuadrado J, Op de Beeck B, Marquardt M, van Dijk P, de Groot JC (2002) Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: multicenter study comparing MR and dual-phase spiral CT. Radiology 223(2):517–524
Scharitzer M, Schima W, Schober E, Reimer P, Helmberger TK, Holzknecht N, Stadler A, Ba-Ssalamah A, Weber M, Wrba F (2005) Characterization of hepatocellular tumors: value of mangafodipir-enhanced magnetic resonance imaging. J Comput Assist Tomogr 29(2):181–190
Helmberger TK, Laubenberger J, Rummeny E, Jung G, Sievers K, Dohring W, Meurer K, Reiser MF (2002) MRI characteristics in focal hepatic disease before and after administration of MnDPDP: discriminant analysis as a diagnostic tool. Eur Radiol 12(1):62–70
Wang C, Ahlstrom H, Eriksson B, Lonnemark M, McGill S, Hemmingsson A (1998) Uptake of mangafodipir trisodium in liver metastases from endocrine tumors. J Magn Reson Imaging 8(3):682–686
Bluemke DA, Weber TM, Rubin D, de Lange EE, Semelka R, Redvanly RD, Chezmar J, Outwater E, Carlos R, Saini S, Holland GA, Mammone JF, Brown JJ, Milestone B, Javitt MC, Jacobs P (2003) Hepatic MR imaging with ferumoxides: multicenter study of safety and effectiveness of direct injection protocol. Radiology 228(2):457–464
Saini S, Stark DD, Hahn PF, Wittenberg J, Brady TJ, Ferrucci JT Jr (1987) Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system. Radiology 162(1 Pt 1):211–216
Reimer P, Muller M, Marx C, Wiedermann D, Muller R, Rummeny EJ, Ebert W, Shamsi K, Peters PE (1998) T1 effects of a bolus-injectable superparamagnetic iron oxide, SH U 555 A: dependence on field strength and plasma concentration—preliminary clinical experience with dynamic T1-weighted MR imaging. Radiology 209(3):831–836
Ba-Ssalamah A, Heinz-Peer G, Schima W, Schibany N, Schick S, Prokesch RW, Kaider A, Teleky B, Wrba F, Lechner G (2000) Detection of focal hepatic lesions: comparison of unenhanced and SHU 555 A-enhanced MR imaging versus biphasic helical CTAP. J Magn Reson Imaging 11(6):665–672
Montet X, Lazeyras F, Howarth N, Mentha G, Rubbia-Brandt L, Becker CD, Vallee JP, Terrier F (2004) Specificity of SPIO particles for characterization of liver hemangiomas using MRI. Abdom Imaging 29(1):60–70
Klatskin GCH (1993) Histopathology of the liver. Oxford University Press, New York
Mortele KJ, Ros PR (2001) Cystic focal liver lesions in the adult: differential CT and MR imaging features. Radiographics 21(4):895–910
Reddy KR, Kligerman S, Levi J, Livingstone A, Molina E, Franceschi D, Badalamenti S, Jeffers L, Tzakis A, Schiff ER (2001) Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. Am Surg 67(2):173–178
Soyer P, Dufresne AC, Somveille E, Scherrer A (1997) Hepatic cavernous hemangioma: appearance on T2-weighted fast spin-echo MR imaging with and without fat suppression. AJR Am J Roentgenol 168(2):461–465
Semelka RC, Brown ED, Ascher SM, Patt RH, Bagley AS, Li W, Edelman RR, Shoenut JP, Brown JJ (1994) Hepatic hemangiomas: a multi-institutional study of appearance on T2-weighted and serial gadolinium-enhanced gradient-echo MR images. Radiology 192(2):401–406
Marti-Bonmati L, Casillas C, Graells M, Masia L (1999) Atypical hepatic hemangiomas with intense arterial enhancement and early fading. Abdom Imaging 24(2):147–152
Danet IM, Semelka RC, Braga L, Armao D, Woosley JT (2003) Giant hemangioma of the liver: MR imaging characteristics in 24 patients. Magn Reson Imaging 21(2):95–101
Bennett GL, Petersein A, Mayo-Smith WW, Hahn PF, Schima W, Saini S (2000) Addition of gadolinium chelates to heavily T2-weighted MR imaging: limited role in differentiating hepatic hemangiomas from metastases. AJR Am J Roentgenol 174(2):477–485
Ba-Ssalamah A, Happel B, Kettenbach J, Dirisamer A, Wrba F, Langle F, Schima W (2004) [MRT of the liver. Clinical significance of nonspecific and liver-specific MRT contrast agents]. Radiologe 44(12):1170–1184
Mitchell DG, Saini S, Weinreb J, De Lange EE, Runge VM, Kuhlman JE, Parisky Y, Johnson CD, Brown JJ, Schnall M et al (1994) Hepatic metastases and cavernous hemangiomas: distinction with standard- and triple-dose gadoteridol-enhanced MR imaging. Radiology 193(1):49–57
Nguyen BN, Flejou JF, Terris B, Belghiti J, Degott C (1999) Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol 23(12):1441–1454
Ba-Ssalamah A, Schima W, Schmook MT, Linnau KF, Schibany N, Helbich T, Reimer P, Laengle F, Wrba F, Kurtaran A, Ryan M, Mann FA (2002) Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents. AJR Am J Roentgenol 179(6):1447–1456
Rummeny E, Weissleder R, Sironi S, Stark DD, Comptom CC, Hahn PF, Saini S, Wittenberg J, Ferrucci JT (1989) Central scars in primary liver tumors: MR features, specificity, and pathologic correlation. Radiology 171(2):323–326
Grazioli L, Morana G, Kirchin MA, Schneider G (2005) Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 236(1):166–177
Grazioli L, Morana G, Federle MP, Brancatelli G, Testoni M, Kirchin MA, Menni K, Olivetti L, Nicoli N, Procacci C (2001) Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine. Radiology 221(3):731–739
Ricci P, Laghi A, Cantisani V, Paolantonio P, Pacella S, Pagliara E, Arduini F, Pasqualini V, Trippa F, Filpo M, Passariello R (2005) Contrast-enhanced sonography with SonoVue: enhancement patterns of benign focal liver lesions and correlation with dynamic gadobenate dimeglumine-enhanced MRI. AJR Am J Roentgenol 184(3):821–827
Bluemke DA, Sahani D, Amendola M, Balzer T, Breuer J, Brown JJ, Casalino DD, Davis PL, Francis IR, Krinsky G, Lee FT Jr., Lu D, Paulson EK, Schwartz LH, Siegelman ES, Small WC, Weber TM, Welber A, Shamsi K (2005) Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology 237(1):89–98
Precetti-Morel S, Bellin MF, Ghebontni L, Zaim S, Opolon P, Poynard T, Mathurin P, Cluzel P (1999) Focal nodular hyperplasia of the liver on ferumoxides-enhanced MR imaging: features on conventional spin-echo, fast spin-echo and gradient-echo pulse sequences. Eur Radiol 9(8):1535–1542
Soe K (1992) Liver Pathology associated with the use of anabolic-androgenic steroids. Liver 12:73–79
Meissner K (1998) Hemorrhage caused by ruptured liver cell adenoma following long-term oral contraceptives: a case report. Hepatogastroenterology 45(19):224–225
Craig CPR, Edmonson HA (1989) Atlas of tumor pathology: tumors of the liver and intrahepatic bile ducts. Armed forces Institute of Pathology, Washington DC
Paulson EK, McClellan JS, Washington K, Spritzer CE, Meyers WC, Baker ME (1994) Hepatic adenoma: MR characteristics and correlation with pathologic findings. AJR Am J Roentgenol 163(1):113–116
Chung KY, Mayo-Smith WW, Saini S, Rahmouni A, Golli M, Mathieu D (1995) Hepatocellular adenoma: MR imaging features with pathologic correlation. AJR Am J Roentgenol 165(2):303–308
Hussain SM, Zondervan PE, Ijzermans JN, Schalm SW, de Man RA, Krestin GP (2002) Benign versus malignant hepatic nodules: MR imaging findings with pathologic correlation. Radiographics 22(5):1023–1036 discussion 1037–1039
Kim MJ, Kim JH, Lim JS, Oh YT, Chung JJ, Choi JS, Lee WJ, Kim KW (2004) Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging 20(4):612–621
Sugarbaker PH, Kemeny N (1989) Management of metastatic cancer to the liver. Adv Surg 22:1–56
Danet IM, Semelka RC, Leonardou P, Braga L, Vaidean G, Woosley JT, Kanematsu M (2003) Spectrum of MRI appearances of untreated metastases of the liver. AJR Am J Roentgenol 181(3):809–817
Stern W, Schick F, Kopp AF, Reimer P, Shamsi K, Claussen CD, Laniado M (2000) Dynamic MR imaging of liver metastases with Gd-EOB-DTPA. Acta Radiol 41(3):255–262
Kim YK, Lee JM, Kim CS (2004) Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. Eur Radiol 14(1):5–13
King LJ, Burkill GJ, Scurr ED, Vlavianos P, Murray-Lyons I, Healy JC (2002) MnDPDP enhanced magnetic resonance imaging of focal liver lesions. Clin Radiol 57(12):1047–1057
Ros PR, Freeny PC, Harms SE, Seltzer SE, Davis PL, Chan TW, Stillman AE, Muroff LR, Runge VM, Nissenbaum MA et al (1995) Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 196(2):481–488
Lai EC, Lau WY (2005) The continuing challenge of hepatic cancer in Asia. Surgeon 3(3):210–215
Mitchell DG (2000) MR imaging of cirrhosis and its complications. Abdom Imaging 25(5):455
Taouli B, Losada M, Holland A, Krinsky G (2004) Magnetic resonance imaging of hepatocellular carcinoma. Gastroenterology 127(5 Suppl 1):S144–S152
Grazioli L, Olivetti L, Fugazzola C, Benetti A, Stanga C, Dettori E, Gallo C, Matricardi L, Giacobbe A, Chiesa A (1999) The pseudocapsule in hepatocellular carcinoma: correlation between dynamic MR imaging and pathology. Eur Radiol 9(1):62–67
Bartolozzi C, Crocetti L, Lencioni R, Cioni D, Della Pina C, Campani D (2007) Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. Eur Radiol 17(10):2519–2530
Muramatsu Y, Nawano S, Takayasu K, Moriyama N, Yamada T, Yamasaki S, Hirohashi S (1991) Early hepatocellular carcinoma: MR imaging. Radiology 181(1):209–213
Grazioli L, Morana G, Caudana R, Benetti A, Portolani N, Talamini G, Colombari R, Pirovano G, Kirchin MA, Spinazzi A (2000) Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings. Invest Radiol 35(1):25–34
Winter TC 3rd, Takayasu K, Muramatsu Y, Furukawa H, Wakao F, Koga H, Sakamoto M, Hirohashi S, Freeny PC (1994) Early advanced hepatocellular carcinoma: evaluation of CT and MR appearance with pathologic correlation. Radiology 192(2):379–387
Pauleit D, Textor J, Bachmann R, Conrad R, Flacke S, Layer G, Kreft B, Schild H (2002) Hepatocellular carcinoma: detection with gadolinium- and ferumoxides-enhanced MR imaging of the liver. Radiology 222(1):73–80
Craig JR, Peters RL, Edmondson HA, Omata M (1980) Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer 46(2):372–379
McLarney JK, Rucker PT, Bender GN, Goodman ZD, Kashitani N, Ros PR (1999) Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation. Radiographics 19(2):453–471
Corrigan K, Semelka RC (1995) Dynamic contrast-enhanced MR imaging of fibrolamellar hepatocellular carcinoma. Abdom Imaging 20(2):122–125
Worawattanakul S, Semelka RC, Noone TC, Calvo BF, Kelekis NL, Woosley JT (1998) Cholangiocarcinoma: spectrum of appearances on MR images using current techniques. Magn Reson Imaging 16(9):993–1003
Maetani Y, Itoh K, Watanabe C, Shibata T, Ametani F, Yamabe H, Konishi J (2001) MR imaging of intrahepatic cholangiocarcinoma with pathologic correlation. AJR Am J Roentgenol 176(6):1499–1507
Zheng WW, Zhou KR, Chen ZW, Shen JZ, Chen CZ, Zhang SJ (2002) Characterization of focal hepatic lesions with SPIO-enhanced MRI. World J Gastroenterol 8(1):82–86
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ba-Ssalamah, A., Uffmann, M., Saini, S. et al. Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions. Eur Radiol 19, 342–357 (2009). https://doi.org/10.1007/s00330-008-1172-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-008-1172-x